Literature DB >> 4610185

Complementation by restricted phage T1.

J R Christensen.   

Abstract

The ability of restricted phage T1hr to complement stocks of T1am mutants carrying the P1 modification has been tested in mixed infection of Escherichia coli B(P1). Of the 18 genes tested, 15 could be complemented to give successful infection of approximately 10 to 25% of the cells, and 2 other genes consistently gave at least 5% complementation. The progeny phage produced in these infections was predominantly of the hr(+)am genotype. A mutant in gene 12 could be complemented very poorly, if at all. With one double mutant stock, the complementation obtained was nearly as good as the more poorly complemented of the two corresponding single mutants.

Entities:  

Mesh:

Year:  1974        PMID: 4610185      PMCID: PMC355669     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  THE COURSE OF INFECTION WITH ABNORMAL BACTERIOPHAGE T4 CONTAINING NON-GLUCOSYLATED DNA ON ESCHERICHIA COLI STRAINS.

Authors:  T FUKASAWA
Journal:  J Mol Biol       Date:  1964-08       Impact factor: 5.469

2.  ON THE MECHANISM OF HOST-INDUCED MODIFICATION. MULTIPLICITY ACTIVATION AND THERMOLABILE FACTOR RESPONSIBLE FOR PHAGE GROWTH RESTRICTION.

Authors:  H UETAKE; S TOYAMA; S HAGIWARA
Journal:  Virology       Date:  1964-02       Impact factor: 3.616

3.  THE FUNCTIONING OF T-EVEN PHAGES WITH UNGLUCOSYLATED DNA IN RESTRICTING ESCHERICHIA COLI HOST CELLS.

Authors:  S HATTMAN
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

4.  Genetic crosses between restricted and unrestricted phage T1 in lysogenic and non-lysogenic hosts.

Authors:  H DREXLER; J R CHRISTENSEN
Journal:  Virology       Date:  1961-01       Impact factor: 3.616

5.  Host-controlled restriction and modification enzymes of Escherichia coli B.

Authors:  S Linn; J A Lautenberger; B Eskin; D Lackey
Journal:  Fed Proc       Date:  1974-05

6.  Functional characterization of the genes of bacteriophage T1.

Authors:  D H Figurski; J R Christensen
Journal:  Virology       Date:  1974-06       Impact factor: 3.616

7.  Synthesis of messenger ribonucleic acid after bacteriophage T1 infection.

Authors:  C J Male; J R Christensen
Journal:  J Virol       Date:  1970-12       Impact factor: 5.103

Review 8.  DNA modification and restriction.

Authors:  W Arber; S Linn
Journal:  Annu Rev Biochem       Date:  1969       Impact factor: 23.643

9.  Nature of Escherichia coli B(P1) yielder cells at the time of infection with restricted T1.

Authors:  L Winstead; H Drexler
Journal:  J Virol       Date:  1969-06       Impact factor: 5.103

10.  [Increased recombination frequency at the ends of T-1-chromosomes].

Authors:  W Michalke
Journal:  Mol Gen Genet       Date:  1967
View more
  4 in total

1.  Recombination in bacteriophage T1 in the presence of host restriction.

Authors:  J S Kotval; T V Potts; J R Christensen
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

2.  Requirement for protein synthesis for survival of unmodified bacteriophage T1 in a restricting host.

Authors:  J S Kotval; J R Christensen
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

3.  Endemic bacteriophages: a cautionary tale for evaluation of bacteriophage therapy and other interventions for infection control in animals.

Authors:  Andrew M Kropinski; Erika J Lingohr; Dianne M Moyles; Shivani Ojha; Amanda Mazzocco; Yi-Min She; Susan J Bach; Erica A Rozema; Kim Stanford; Tim A McAllister; Roger P Johnson
Journal:  Virol J       Date:  2012-09-17       Impact factor: 4.099

4.  Combined behavioral and electrophysiological evidence for a direct cortical effect of prefrontal tDCS on disorders of consciousness.

Authors:  Jacobo D Sitt; Lionel Naccache; Bertrand Hermann; Federico Raimondo; Lukas Hirsch; Yu Huang; Mélanie Denis-Valente; Pauline Pérez; Denis Engemann; Frédéric Faugeras; Nicolas Weiss; Sophie Demeret; Benjamin Rohaut; Lucas C Parra
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.